48
Participants
Start Date
April 12, 2022
Primary Completion Date
July 15, 2024
Study Completion Date
July 31, 2026
BI 765063
BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
Ezabenlimab
Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
BI 836880
BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
Cetuximab
Cetuximab
Investigator´s Choice Chemotherapy
Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
King Chulalongkorn Memorial Hospital, Bangkok
HOP Timone, Marseille
CTR Georges-François Leclerc, Dijon
Hospital Clínico San Carlos, Madrid
INS Claudius Regaud IUCT-Oncopole, Toulouse
Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V., Zapopan
HOP Civil, Strasbourg
CTR Leon Berard, Lyon
INS Curie, Paris
Hospital Sultan Ismail, Johor Bahru
Valkyrie Clinical Trials, Los Angeles
Songklanagarind Hospital, Songkhla
FAICIC S de RL de C.V., Veracruz
Sarawak General Hospital, Kuching, Sarawak
"Institutul Oncologic Prof. Dr. Ion Chiricuta", Cluj-Napoca
Japanese Foundation for Cancer Research, Tokyo, Koto-ku
ARKE SMO S.A. de C.V, Mexico City
ARENSIA Exploratory Medicine, Chisinau
Mandziuk Slawomir Specialist Medical Practice, Lublin
"Prof. Dr. Alexandru Trestioreanu Oncology Institut", Bucharest
Hospital Vall d'Hebron, Barcelona
Hospital Duran i Reynals, L'Hospitalet de Llobregat
King's College Hospital, London
The Royal Marsden Hospital, Chelsea, London
Hammersmith Hospital, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY